RENEW OR SUBSCRIBE TO PPM
Subscription is FREE for qualified healthcare professionals in the US.

FDA Clears New Neurostimulation Device for Opioid Withdrawal

Wearable device relieves early detoxification symptoms

A PPM Brief

FDA has approved the auricular neurostimulation device Drug Relief, from DyAnsys (San Mateo, CA), the company announced.1 Drug Relief is a wearable, percutaneous electrical nerve field stimulator that sends electrical pulses through tiny needles in the ear to alleviate symptoms such as anxiety, agitation, depression, nausea, and opioid cravings. The device, which promotes patient comfort and mobility, is designed to administer treatment over the course of five days.

“We are in a full-blown crisis and we need non-narcotic options and alternatives like this that can make a significant difference for individual patients and their families,” said DyAnsys CEO Srini Nageshwar in a company press release.

The device is indicated for use in reducing the symptoms of opioid withdrawal as part of a comprehensive rehabilitation program. Specifically, Drug Relief works to stabilize a patient during the early stages of withdrawal before potential medication-assisted treatment begins. According to the press release, patients may see a reduction in the symptoms of opioid withdrawal within 30 to 60 minutes of beginning treatment.

Last updated on: June 25, 2018
Continue Reading:
NeuroMetrix, GSK Consumer to Expand Wearable Pain Relief Technology
SHOW MAIN MENU
SHOW SUB MENU